The Financial Times covered our latest ground-breaking research, showing that gene screening can cut early disease deaths by 25%. A simple genetic screening test has the potential to stop almost a quarter of premature preventable deaths from common diseases including breast cancer, diabetes and hypertension, by identifying those most at risk.

Our research shows very high risk individuals reached the risk levels associated with usual starting screening ages 12.4 years earlier, on average. In other words, if a screening programme were devised on the basis of the average risk facing a 50-year-old, this high risk group would have the same predicted risk at the age of 37.6. Recommendations for earlier screening for genetically very high risk groups ranged from four years in advance for abdominal aortic aneurysm, to 22 years for hypertension.

The Telegraph covered our latest study on obesity, which showed that individuals with a genetic risk score for high BMI, calculated using Genomics’ proprietary polygenic risk scores (PRS), were 10 times more likely to develop obesity later in life - even at the same activity levels and calorie intake.

Our research shows that those at high genetic risk of obesity will need personalised support to help them stay at, or return to, a healthy weight.

Genomics releases new research showing significant link between genetic risk and obesity

Genomics announces the appointment of David Thornton to the position of President, succeeding Professor Gil McVean, who will join the board as a non-executive Director.

The Times covers a new study that has claimed that thousands of heart attacks and strokes could be prevented by incorporating people’s genetic risk into their standard middle-aged health check. Researchers have identified a suite of genetic changes, affecting 1 in 12 Britons, that significantly raise the chance of suffering heart disease.

Research by Genomics plc has identified that 8% of the adult population have the same risk of heart disease due to polygenic risk, as carriers of rare genetic mutations that cause familial hypercholesterolemia (FH).

Genomics has published groundbreaking research revealing that 8% of the UK's adult population carries a polygenic risk for heart disease equivalent to that of carriers of Familial Hypercholesterolemia (FH). This polygenic group, previously undetected by the NHS, accounts for a significant portion of early heart disease cases—18 times more than those caused by FH.

Mount Sinai Health System is launching a center that will conduct genetic-based research on undiagnosed medical conditions. The system's Center for Undiagnosed Diseases will open early next year, the latest evidence of the money providers are pouring into genomics. Mount Sinai said Tuesday the center will be home to New York City's first undiagnosed disease network, which connects clinicians across the U.S. conducting this kind of research.